{
    "2018-08-28": [
        [
            {
                "time": "",
                "original_text": "半年报数据显示：复星、中国医药营收达百亿，科伦净利迅增，泰格研发投入超销售费用",
                "features": {
                    "keywords": [
                        "半年报",
                        "复星",
                        "中国医药",
                        "科伦",
                        "泰格",
                        "研发投入",
                        "销售费用"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药中报点评：主业略超预期，股权激励护航未来三年高增长",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "中报",
                        "主业",
                        "股权激励",
                        "高增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[增持评级] 泰格医药(300347)中报点评：环比增速继续提升 全面受益创新崛起",
                "features": {
                    "keywords": [
                        "增持评级",
                        "泰格医药",
                        "中报",
                        "环比增速",
                        "创新崛起"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【西南医药朱国广团队】泰格医药（300347）业绩符合预期，期权激励保障快速增长",
                "features": {
                    "keywords": [
                        "西南医药",
                        "朱国广团队",
                        "泰格医药",
                        "业绩",
                        "期权激励",
                        "快速增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[审慎增持评级] 泰格医药(300347)中报点评：业绩保持快速增长 激励计划彰显对公司未来发展信心",
                "features": {
                    "keywords": [
                        "审慎增持评级",
                        "泰格医药",
                        "中报",
                        "业绩",
                        "快速增长",
                        "激励计划",
                        "未来发展信心"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级] 泰格医药(300347)中报点评：业绩符合预期 股权激励利于人才储备",
                "features": {
                    "keywords": [
                        "推荐评级",
                        "泰格医药",
                        "中报",
                        "业绩",
                        "股权激励",
                        "人才储备"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}